Confirmatory testing of hepatitis C virus-positive enzyme immunoassay results in limited-resource countries: Should it be attempted?

Transfusion

Volumn 48, Issue 6, 2008, Pages 1239-1244

  Nelson, Kenrad E ^a   Shan, Hua ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; ILLICIT DRUG;

ACUPUNCTURE; BLOOD DONOR; BLOOD SAMPLING; CIRCUMCISION; ENZYME IMMUNOASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER FAILURE; NOTE; NUCLEIC ACID AMPLIFICATION; PREVALENCE; PUBLIC HEALTH PROBLEM; SCAR FORMATION; SCREENING; SEROLOGY; VIRAL CONTAMINATION;

HEALTH RESOURCES; HEPACIVIRUS; HUMANS; IMMUNOENZYME TECHNIQUES;

EID: 44849087382     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01696.x     Document Type: Note

References (36)

1. World Health Organization. Hepatitis C global prevalence. Wkly Epidemiol Rep 1997 72 : 341 4.
2. Madhava V, Burgess L, Drucker E. Epidemiology of chronic hepatitis C virus infection in Sub-Saharan Africa. Lancet Infect Dis 2002 2 : 293 302.
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999 341 : 556 62.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 : 705 14.
5. Centers for Disease Control and Prevention. Hepatitis Surveillance Report Number 58. Available from http://www.cdc.gov/ncidod/diseases/hepatitis/ bibliolcdc
6. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007 13 : 2436 41.
7. Orland IR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2000 33 : 321 7.
8. Kleinman SH, Stramer SL, Brodsky JP, Caglioti S, Busch MP. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion 2006 46 : 695 702.
9. Busch MP, Glynn SA, Stramer SL, Orland J, Murphy E, Wright DJ, Kleinman S. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006 46 : 469 75.
10. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 5.
11. FDA. Guidance for industry: supplemental testing and the notification of consignees of donor test results for antibody to hepatitis C virus. Fed Regist 1998 63 (54 1375 6.
12. Colver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted look back for HCV infection in the United States - interview results. Transfusion 2000 40 : 1176 81.
13. Armstrong GL, Alter MJ, Quillan GM, Margolis HS. The past incidence of hepatitis C virus: implications for the future burden of chronic liver disease in the United States. Hepatology 2000 35 : 777 82.
14. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003 139 : 817 23.
15. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
16. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel. M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alpha2-b. N Engl J Med 2001 345 : 1452 9.
17. World Health Organization. Global database on blood safety, Report 2001-2002. Geneva : Blood Transfusion Safety Essential Health Technologies, World Health Organization, WHO Press, 2004.
18. Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006 44 : 455 61.
19. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: world-based regional estimates. Bull World Health Organ 1999 77 : 806 12.
20. Simonsen C, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of blood borne pathogens: a review. Bull World Health Organ 1999 77 : 789 800.
21. Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg 2002 66 : 389 93.
22. Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Chaudhuri S, Maity SG, Naik TN, Bhattacharya SK, Mazumder DN. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 2003 37 : 802 9.
23. Ahmad K. Pakistan: a cirrhotic state? Lancet 2004 364 : 1843 4.
24. Shan A, Wang JX, Ren FR, Zhang YZ, Zhao HY, Gao GJ, Ji Y, Ness PM. Blood banking in China. Lancet 2002 360 : 1770 5.
25. Zaller N, Nelson KE, Aladashvili M, Badvidze N, del Rio C, Tsertsvadze T. Risk factors for hepatitis C virus infection among blood donors in the Republic of Georgia. Eur J Epidemiol 2004 19 : 547 53.
26. Thaikruea L, Nelson KE, Thongsawat S, Maneekarn N, Netski D, Thomas DL. Risk factors for hepatitis C virus infection among blood donors in northern Thailand. Transfusion 2004 44 : 1433 40.
27. Luby S, Khanani R, Zia M, Vellani Z, Ali M, Qureshi AH, Khan AJ, Mujeeb SA, Shah SA, Fisher-Hoch S. Evaluation of blood bank practices in Karachi, Pakistan, and the government's response. Health Policy Planning 2000 15 : 217 22.
28. Prati D. Transmission of hepatitis C virus by blood transfusion and other medical procedures: a global review. J Hepatol 2006 45 : 607 16.
29. Stvilia K, Tsertsvadze T, Sharvadze L, del Rio C, Kuniholm M, Nelson KE. Prevalence of hepatitis C, HIV and risk behavior for blood-borne infections: a population-based survey of the adult population of Tbilisi, Republic of Georgia. J Urban Health 2006 83 : 289 98.
30. Hladik W, Kataaha P, Mermin J, Purdy M, Otekat G, Lackritz E, Alter MJ, Downing R. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health 2006 11 : 951 4.
31. Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injection and the emergence of human pathogens. Lancet 2001 358 : 1989 92.
32. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Morb Mortal Wkly Rep 2003 52, No. RR-301-15.
33. Ren FR, Lu QS, Zhuang H, Li JJ, Gong XY, Gao GJ, Liu CL, Wang JX, Yao FZ, Zheng YR, Zhu FM, Tiemuer MH, Bai XH, Shan H. Significance of the signed-to-cutoff ratios of antihepatitis C virus enzyme immunoassays in screening of Chinese donors. Transfusion 2005 45 : 1816 22.
34. Hutin YJ, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003 327 : 1075.
35. Brewer DD, Brody S, Drucker E, Gisselquist D, Minkin SF, Potterat JJ, Rothenberg RB, Vachon F. Mounting anomalies in the epidemiology of HIV in Africa: cry the beloved paradigm. Int J STD AIDS 2003 14 : 144 7.
36. DesJarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein RS. Variability on the incidence of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003 157 : 467 71.